Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient

Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient

Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primari...

Cell-mediated immune reactivity in liver disease.

Cell-mediated immunity has been investigated using the leucocyte migration test in 32 patients with chronic active hepatitis or primary biliary cirrhosis. Twenty-six (75%) showed reactivity to liver extract. At least two antigens are involved. Cell-mediated reactivity was confirmed in some cases using lymphocyte ;blast' transformation. There was no correlation with the presence of auto-antibodi...

Immunosuppressive therapy for canine immune-mediated hemolytic anemia.

The mortality for dogs with severe immune-mediated hemolytic anemia (IMHA) is unacceptably high, and better immunosuppressive regimens are needed to increase survival. Understanding the basic immunology of the disease and the mechanisms of action of the available immunosuppressive therapies will help clinicians choose an appropriate immunosuppressive protocol. Prospective, randomized clinical s...

Inflammatory Bowel Disease in Primary Sclerosing Cholangitis: Clinical Characteristics in Liver Transplanted and Non-Transplanted Patients

Inflammatory bowel disease in liver transplanted patients

Most common hepatobiliary manifestation of inflammatory bowel disease (IBD) are primary sclerosing cholangitis (PSC) and autoimmune hepatitis, ranking them as the main cause of liver transplantation (LT) in IBD setting. Course of pre-existing IBD after LT differs depending on many transplant related factors. Potential risk factors related to IBD deterioration after LT are tacrolimus-based immun...